| Over a week ago | ||||
Keros Therapeutics… Keros Therapeutics announced that it presented additional biomarker data from its completed Phase 1 clinical trial of KER-012 in healthy post-menopausal women at the American Thoracic Society, ATS, 2023 International Conference, held from May 19 through May 24, 2023. In addition, Keros presented preclinical data showing the potential of a research form of KER-012 to improve left ventricular function in a mouse model of left ventricular pressure overload, as well as preclinical data evaluating transforming growth factor-beta signaling in two major cell types involved in the dysregulated vascular remodeling in pulmonary arterial hypertension, and KER-012's effect on this ligand-induced signaling. "We are pleased to present clinical and preclinical data from our KER-012 program at the ATS conference this year. The preclinical presentations demonstrate observed ligand selectivity of KER-012 and changes in inflammation and fibrosis in models of PAH and cardiovascular diseases. From our completed Phase 1 clinical trial of KER-012 in healthy post-menopausal women, we presented new data with observed sustained changes in serum biomarkers of cardiac dysfunction, inflammation and fibrosis," said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer of Keros. "We believe these data support the potential of KER-012 to treat fibrosis and inflammation in patients with PAH and in patients with cardiovascular disease." | ||||
Piper Sandler analyst… Piper Sandler analyst Joseph Catanzaro lowered the firm's price target on Keros Therapeutics to $110 from $120 and keeps an Overweight rating on the shares. The analyst cites higher operational spend post the Q1 results for the target drop. | ||||
| Over a month ago | ||||
Keros' cash and cash… Keros' cash and cash equivalents as of March 31 was $351.4M compared to $279M as of December 31, 2022. Keros expects that the cash and cash equivalents it had on hand at March 31, 2023 will enable Keros to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2025. | ||||
Keros Therapeutics… Keros Therapeutics announced that it appointed Alpna Seth, Ph.D., to its Board of Directors, effective May 1, 2023. Dr. Seth served as the President and Chief Executive Officer of Nura Bio Inc. for three years, until she retired in October 2022. | ||||
Virtual Meeting to be… Virtual Meeting to be held on March 24 hosted by Piper Sandler. | ||||
Virtual Meeting to be… Virtual Meeting to be held on March 24 hosted by Piper Sandler. | ||||
| Over a quarter ago | ||||
"2022 was another… "2022 was another momentous year for Keros - consistent execution throughout last year has positioned Keros to deliver on several key upcoming milestones in 2023," said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer. "We are excited by the momentum and engagement around our two ongoing Phase 2 clinical trials of KER-050, one in patients with myelodysplastic syndromes ("MDS") and one in patients with myelofibrosis, as we believe KER-050 has significant potential to address unmet patient need in a differentiated way. Additionally, we will continue to leverage our understanding of the transforming growth factor-beta family of proteins to research our library of proprietary molecules, in order to expand our development programs related to hematological, pulmonary and cardiovascular disorders." | ||||
Cowen analyst Tyler Van… Cowen analyst Tyler Van Buren initiated coverage of Keros Therapeutics with an Outperform rating. The analyst says the company's KER-050 and KER-012 improve upon Reblozyl and sotatercept, respectively. KER-050 has demonstrated more robust erythropoiesis across transfusion burden and ring sideroblasts status with a thrombopoiesis kicker, and updates this year could demonstrate superior durability, the analyst tells investors in a research note. The firm says significant value creation will occur in the shares if either drug works. | ||||
BTIG analyst Julian… BTIG analyst Julian Harrison raised the firm's price target on Keros Therapeutics to $105 from $95 and keeps a Buy rating on the shares following its "comprehensive update" for KER-050 and KER-047 at ASH. KER-050's differentiation vs. Luspatercept continues to materialize, the analyst tells investors in a research note, stating that he sees significant points of contrast that should open the door for the drug to a much broader commercial opportunity in MDS. | ||||
In conjunction with the… In conjunction with the 2022 ASH Annual Meeting, Biotechnology Analyst Harrison holds a group dinner in New Orleans on December 12 at 8 pm hosted by BTIG. | ||||
